Back to search

Article

Pharmacovigilance analysis of inclisiran:a real-world assessment based on the FAERS database

2025-03-06

Abstract excerpt

<h4>Background: </h4> :Inclisiran, a novel small interfering RNA (siRNA) therapy targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), has demonstrated efficacy in lowering low-density lipoprotein cholesterol (LDL-C). While generally well-tolerated, emerging evidence has highlighted safety concerns, particularly joint-related adverse events (AEs), such as arthralgia. atorvastatin, a commonly prescribed...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1113137b-a2cb-5da6-b699-13fdc16f79e2
DOI
10.22541/au.174127529.93210053/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Pharmacovigilance analysis of inclisiran:a real-world assessment based on the FAERS databaseDOI 10.22541/au.174127529.93210053/v1
Select a neighboring publication to make it the new centre.